Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 11/20 | 0.71 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23809696 | 1.00 | ADK (0.71) | ADKCCNA2CDK2CCNA1 | |
| SCHEMBL21369236 | 0.84 | ADK (0.60) | ADK | |
| SCHEMBL21368953 | 0.84 | ADK (0.71) | ADK | |
| SCHEMBL21368891 | 0.83 | ADK (0.73) | ADKCCNA2CDK2CCNA1 | |
| SCHEMBL19837976 | 0.83 | ADK (1.00) | ADKCCNA2CDK2CCNA1 | |
| SCHEMBL21369238 | 0.82 | ADK (0.48) | ADKCCNA2CDK2CCNA1 | |
| SCHEMBL21369234 | 0.82 | CDK5 (0.58) | ADKCCNA2CDK2CCNA1 | |
| SCHEMBL21368954 | 0.81 | ADK (0.47) | ADK | |
| SCHEMBL23809695 | 0.81 | ADK (0.46) | ADKCCNA2CDK2CCNA1 | |
| SCHEMBL20973132 | 0.81 | ADK (0.69) | ADKCCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210002321-A1 | SUBSTITUTED PYRIDOPYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USES | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2021-01-07 | — | — | US | disclosed |
| WO-2019174657-A1 | SUBSTITUTED PYRIDOPYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USES | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002321-A1 | SUBSTITUTED PYRIDOPYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USES | TYMP, DPYD, RRM2 | ADK 539/4885CCNA2 498/4885CDK2 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.